Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial

We evaluated the triplet regimen obinutuzumab-atezolizumab-lenalidomide (G-atezo-len) for patients with relapsed/refractory (R/R) follicular lymphoma (FL) in an open-label, multicenter phase Ib/II study (BO29562; NCT02631577). An initial 3 + 3 dose‐escalation phase to define the recommended phase II...

Descripción completa

Detalles Bibliográficos
Autores principales: Morschhauser, Franck, Ghosh, Nilanjan, Lossos, Izidore S., Palomba, M. Lia, Mehta, Amitkumar, Casasnovas, Olivier, Stevens, Don, Katakam, Sudhakar, Knapp, Andrea, Nielsen, Tina, McCord, Ron, Salles, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379261/
https://www.ncbi.nlm.nih.gov/pubmed/34417444
http://dx.doi.org/10.1038/s41408-021-00539-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379261/
https://www.ncbi.nlm.nih.gov/pubmed/34417444
http://dx.doi.org/10.1038/s41408-021-00539-8

Ejemplares similares